Vinorelbine
Adult Nasal Type Extranodal NK/T-Cell Lymphoma
National Cancer Institute (NCI)Phase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 81/ 100
Competitive context
1 Active assets in the Adult Nasal Type Extranodal NK/T-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Azacitidine Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 2 | B |
Alisertib National Cancer Institute (NCI) | Phase 2 | B |
Veliparib National Cancer Institute (NCI) | Phase 1/2 | CCC |
Dasatinib National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Vinorelbine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →